Krebs bei unbekanntem Primärtumor

Comparing targeted therapy or immunotherapy vs platinum-based chemotherapy in CUP

Stadium

Stadium II

Offizieller Titel

A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy

Kurzbeschreibung

This study will compare the efficacy and safety of molecularly-guided therapy versus standard platinum-containing chemotherapy in participants with cancer of unknown primary site (CUP; non-specific subset) who have achieved disease control after 3 cycles of first-line platinum doublet induction chemotherapy.

Kurztitel / NCT-Nr. / Sponsor / Start

CUPISCO
NCT03498521
Hoffmann-La Roche
November 2018

Kontakt

Dr. Dr. Christian Britschgi
Christian.britschgi@usz.ch
Telefon: 044 255 22 14


Wir verwenden Cookies, um unsere Website nutzerfreundlich zu gestalten, sie fortlaufend zu verbessern und die Zugriffe auf unsere Website zu analysieren. Mit der Nutzung unserer Dienste erklären Sie sich damit einverstanden. Weitere Informationen finden Sie in unserer Datenschutzerklärung.